Pain Management Drugs Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, Opioids, Anesthetics, Antidepressants, Anticonvulsants), By Indication (Acute Pain, Neuropathic Pain), By Distribution Channel, By Region, And Segment Forecasts, 2025
Description
Pain Management Drugs Market Summary
The global pain management drugs market size was estimated at USD 78.84 billion in 2024 and is projected to reach USD 115.92 billion by 2033, growing at a CAGR of 4.38% from 2025 to 2033. The rising prevalence of chronic pain conditions across aging and lifestyle-affected populations drives the growth of the global pain management drugs market.
Increasing cases of arthritis, cancer-related pain, lower back disorders, neuropathic pain, and post-surgical discomfort have intensified the demand for effective pharmacological interventions. The growing burden of musculoskeletal and neurological disorders has expanded the patient pool requiring long-term pain therapy. Healthcare providers are adopting advanced pain management approaches to enhance quality of life and reduce healthcare burden. In addition, the growing awareness of pain as a treatable clinical condition has supported early diagnosis and treatment. The rising number of surgical procedures globally further contributes to the higher consumption of analgesics and opioids, strengthening the need for targeted and multimodal pain management therapies.
The market expansion is further supported by continuous innovation in non-opioid pain medications and novel drug delivery technologies. For instance, in January 2025, TIME reported that the U.S. Food and Drug Administration (FDA) approved suzetrigine, marketed as Journavx by Vertex Pharmaceuticals, as the first new class of non-opioid pain medication in over 20 years. Suzetrigine is a 50 mg oral tablet taken twice daily and targets the Nav1.8 sodium channel, specific to pain neurons, thereby avoiding the addictive potential of opioids. In clinical trials involving patients recovering from bunionectomy and abdominoplasty surgeries, 83% and 61% of participants taking suzetrigine, respectively, reported at least a 30% reduction in pain, compared to 68% and 48% in the placebo groups. These results suggest that suzetrigine may offer a safer alternative to opioids for managing acute pain. Pharmaceutical companies also focus on developing safer formulations, while advancements in extended-release and transdermal drugs improve efficacy, convenience, and patient adherence.
Regulatory oversight continues to shape market trends. For instance, on March 12, 2025, the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Commission on Human Medicines (CHM) published a report detailing the removal of the post-operative pain indication from all modified-release opioids due to safety concerns, including persistent post-operative opioid use (PPOU) and opioid-induced ventilatory impairment (OIVI). PPOU occurred in 2% to 44% of patients treated with prolonged-release opioids, rising to 60% in those previously using these opioids, while OIVI incidence ranged from 0.4% to 41%. Consequently, the MHRA recommended that only immediate-release opioids be prescribed for short-term post-operative pain and encouraged smaller pack sizes to reduce over-prescription. Overall, growing R&D in non-addictive analgesics, personalized therapies, digital monitoring tools, and expanded healthcare access is fueling the sustained growth of the pain management drugs market globally.
Global Pain Management Drugs Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pain management drugs market report based on drug class, indication, distribution channel and region:
The global pain management drugs market size was estimated at USD 78.84 billion in 2024 and is projected to reach USD 115.92 billion by 2033, growing at a CAGR of 4.38% from 2025 to 2033. The rising prevalence of chronic pain conditions across aging and lifestyle-affected populations drives the growth of the global pain management drugs market.
Increasing cases of arthritis, cancer-related pain, lower back disorders, neuropathic pain, and post-surgical discomfort have intensified the demand for effective pharmacological interventions. The growing burden of musculoskeletal and neurological disorders has expanded the patient pool requiring long-term pain therapy. Healthcare providers are adopting advanced pain management approaches to enhance quality of life and reduce healthcare burden. In addition, the growing awareness of pain as a treatable clinical condition has supported early diagnosis and treatment. The rising number of surgical procedures globally further contributes to the higher consumption of analgesics and opioids, strengthening the need for targeted and multimodal pain management therapies.
The market expansion is further supported by continuous innovation in non-opioid pain medications and novel drug delivery technologies. For instance, in January 2025, TIME reported that the U.S. Food and Drug Administration (FDA) approved suzetrigine, marketed as Journavx by Vertex Pharmaceuticals, as the first new class of non-opioid pain medication in over 20 years. Suzetrigine is a 50 mg oral tablet taken twice daily and targets the Nav1.8 sodium channel, specific to pain neurons, thereby avoiding the addictive potential of opioids. In clinical trials involving patients recovering from bunionectomy and abdominoplasty surgeries, 83% and 61% of participants taking suzetrigine, respectively, reported at least a 30% reduction in pain, compared to 68% and 48% in the placebo groups. These results suggest that suzetrigine may offer a safer alternative to opioids for managing acute pain. Pharmaceutical companies also focus on developing safer formulations, while advancements in extended-release and transdermal drugs improve efficacy, convenience, and patient adherence.
Regulatory oversight continues to shape market trends. For instance, on March 12, 2025, the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Commission on Human Medicines (CHM) published a report detailing the removal of the post-operative pain indication from all modified-release opioids due to safety concerns, including persistent post-operative opioid use (PPOU) and opioid-induced ventilatory impairment (OIVI). PPOU occurred in 2% to 44% of patients treated with prolonged-release opioids, rising to 60% in those previously using these opioids, while OIVI incidence ranged from 0.4% to 41%. Consequently, the MHRA recommended that only immediate-release opioids be prescribed for short-term post-operative pain and encouraged smaller pack sizes to reduce over-prescription. Overall, growing R&D in non-addictive analgesics, personalized therapies, digital monitoring tools, and expanded healthcare access is fueling the sustained growth of the pain management drugs market globally.
Global Pain Management Drugs Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pain management drugs market report based on drug class, indication, distribution channel and region:
- Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
- NSAIDs
- Opioids
- Anesthetics
- Antidepressants
- Anticonvulsants
- Others
- Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Acute Pain (Postoperative, Injury-Related, Musculoskeletal)
- Chronic Musculoskeletal Pain / Osteoarthritis / Low Back Pain
- Neuropathic Pain (Diabetic Neuropathy, Postherpetic Neuralgia, Fibromyalgia)
- Migraine (Acute & Preventive)
- Cancer Pain
- Post-Surgical / Hospital-Based Procedural Pain (short duration)
- Others
- Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Online Pharmacy
- Retail Pharmacy
- Hospital Pharmacy
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Drug Class
- 1.2.2. Indication
- 1.2.3. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR’s Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
- Chapter 3. Pain Management Drugs Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter’s Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Pricing Analysis
- Chapter 4. Pain Management Drugs Market: Drug Class Business Analysis
- 4.1. Drug Class Market Share, 2024 & 2033
- 4.2. Drug Class Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
- 4.4. NSAIDs
- 4.4.1. NSAIDs Market, 2021 - 2033 (USD Million)
- 4.5. Opioids
- 4.5.1. Opioids Market, 2021 - 2033 (USD Million)
- 4.6. Anesthetics
- 4.6.1. Anesthetics Market, 2021 - 2033 (USD Million)
- 4.7. Antidepressants
- 4.7.1. Antidepressants Market, 2021 - 2033 (USD Million)
- 4.8. Anticonvulsants
- 4.8.1. Anticonvulsants Market, 2021 - 2033 (USD Million)
- 4.9. Others
- 4.9.1. Others Market, 2021 - 2033 (USD Million)
- Chapter 5. Pain Management Drugs Market: Indication Business Analysis
- 5.1. Indication Market Share, 2024 & 2033
- 5.2. Indication Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
- 5.4. Acute Pain (Postoperative, Injury-Related, Musculoskeletal)
- 5.4.1. Acute Pain (Postoperative, Injury-Related, Musculoskeletal) Market, 2021 - 2033 (USD Million)
- 5.5. Chronic Musculoskeletal Pain / Osteoarthritis / Low Back Pain
- 5.5.1. Chronic Musculoskeletal Pain / Osteoarthritis / Low Back Pain Market, 2021 - 2033 (USD Million)
- 5.6. Neuropathic Pain (Diabetic Neuropathy, Postherpetic Neuralgia, Fibromyalgia)
- 5.6.1. Neuropathic Pain (Diabetic Neuropathy, Postherpetic Neuralgia, Fibromyalgia) Market, 2021 - 2033 (USD Million)
- 5.7. Migraine (Acute & Preventive)
- 5.7.1. Migraine (Acute & Preventive) Market, 2021 - 2033 (USD Million)
- 5.8. Cancer Pain
- 5.8.1. Cancer Pain Market, 2021 - 2033 (USD Million)
- 5.9. Post-Surgical / Hospital-Based Procedural Pain (short duration)
- 5.9.1. Post-Surgical / Hospital-Based Procedural Pain (short duration) Market, 2021 - 2033 (USD Million)
- 5.10. Others
- 5.10.1. Others Market, 2021 - 2033 (USD Million)
- Chapter 6. Pain Management Drugs Market: Distribution Channel Business Analysis
- 6.1. Distribution Channel Market Share, 2024 & 2033
- 6.2. Distribution Channel Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
- 6.4. Online Pharmacy
- 6.4.1. Online Pharmacy Market, 2021 - 2033 (USD Million)
- 6.5. Retail Pharmacy
- 6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Million)
- 6.6. Hospital Pharmacy
- 6.6.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)
- Chapter 7. Pain Management Drugs Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2033
- 7.2. Regional Market Dashboard
- 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 7.4. North America
- 7.4.1. North America Pain Management Drugs Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Target Disease Prevalence
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. Reimbursement Framework
- 7.4.2.5. U.S. Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Target Disease Prevalence
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Reimbursement Framework
- 7.4.3.5. U.S. Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Target Disease Prevalence
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. Reimbursement Framework
- 7.4.4.5. Mexico Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Europe
- 7.5.1. Europe Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Target Disease Prevalence
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Reimbursement Framework
- 7.5.2.5. Uk Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Target Disease Prevalence
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Reimbursement Framework
- 7.5.3.5. Germany Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Target Disease Prevalence
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. Reimbursement Framework
- 7.5.4.5. France Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Target Disease Prevalence
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Reimbursement Framework
- 7.5.5.5. Italy Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Target Disease Prevalence
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Reimbursement Framework
- 7.5.6.5. Spain Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Target Disease Prevalence
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Reimbursement Framework
- 7.5.7.5. Denmark Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Target Disease Prevalence
- 7.5.8.3. Regulatory Framework
- 7.5.8.4. Reimbursement Framework
- 7.5.8.5. Sweden Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Target Disease Prevalence
- 7.5.9.3. Regulatory Framework
- 7.5.9.4. Reimbursement Framework
- 7.5.9.5. Norway Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Target Disease Prevalence
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Reimbursement Framework
- 7.6.2.5. Japan Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Target Disease Prevalence
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Reimbursement Framework
- 7.6.3.5. China Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Target Disease Prevalence
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. Reimbursement Framework
- 7.6.4.5. India Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Target Disease Prevalence
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Reimbursement Framework
- 7.6.5.5. Australia Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Target Disease Prevalence
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. Reimbursement Framework
- 7.6.6.5. South Korea Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Target Disease Prevalence
- 7.6.7.3. Regulatory Framework
- 7.6.7.4. Reimbursement Framework
- 7.6.7.5. Thailand Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Target Disease Prevalence
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Reimbursement Framework
- 7.7.2.5. Japan Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Target Disease Prevalence
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Reimbursement Framework
- 7.7.3.5. China Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Target Disease Prevalence
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. Reimbursement Framework
- 7.8.2.5. South Africa Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Target Disease Prevalence
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. Reimbursement Framework
- 7.8.3.5. Saudi Arabia Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Target Disease Prevalence
- 7.8.4.3. Regulatory Framework
- 7.8.4.4. Reimbursement Framework
- 7.8.4.5. UAE Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Target Disease Prevalence
- 7.8.5.3. Regulatory Framework
- 7.8.5.4. Reimbursement Framework
- 7.8.5.5. Kuwait Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Participant Overview
- 8.2. Company Market Position Analysis
- 8.3. Company Categorization
- 8.4. Strategy Mapping
- 8.5. Company Profiles/Listing
- 8.5.1. Teva Pharmaceutical
- 8.5.1.1. Overview
- 8.5.1.2. Financial Performance
- 8.5.1.3. Product Benchmarking
- 8.5.1.4. Strategic Initiatives
- 8.5.2. Pfizer
- 8.5.2.1. Overview
- 8.5.2.2. Financial Performance
- 8.5.2.3. Product Benchmarking
- 8.5.2.4. Strategic Initiatives
- 8.5.3. Abbott
- 8.5.3.1. Overview
- 8.5.3.2. Financial Performance
- 8.5.3.3. Product Benchmarking
- 8.5.3.4. Strategic Initiatives
- 8.5.4. Mallinckrodt Pharmaceuticals
- 8.5.4.1. Overview
- 8.5.4.2. Financial Performance
- 8.5.4.3. Product Benchmarking
- 8.5.4.4. Strategic Initiatives
- 8.5.5. Endo International
- 8.5.5.1. Overview
- 8.5.5.2. Financial Performance
- 8.5.5.3. Product Benchmarking
- 8.5.5.4. Strategic Initiatives
- 8.5.6. GlaxoSmithKline
- 8.5.6.1. Overview
- 8.5.6.2. Financial Performance
- 8.5.6.3. Product Benchmarking
- 8.5.6.4. Strategic Initiatives
- 8.5.7. AstraZeneca
- 8.5.7.1. Overview
- 8.5.7.2. Financial Performance
- 8.5.7.3. Product Benchmarking
- 8.5.7.4. Strategic Initiatives
- 8.5.8. Depomed
- 8.5.8.1. Overview
- 8.5.8.2. Financial Performance
- 8.5.8.3. Product Benchmarking
- 8.5.8.4. Strategic Initiatives
- 8.5.9. Merck
- 8.5.9.1. Overview
- 8.5.9.2. Financial Performance
- 8.5.9.3. Product Benchmarking
- 8.5.9.4. Strategic Initiatives
- 8.5.10. Novartis
- 8.5.10.1. Overview
- 8.5.10.2. Financial Performance
- 8.5.10.3. Product Benchmarking
- 8.5.10.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
